UCLA Health’s Outpatient Theranostics Center allows clinicians to treat up to 16 patients per day with Pluvicto and other ...

Patient was not fit for Docetaxel therapy and he was put on monthly Denosumab injection 120 mg/1 syringe, and Abiraterone ...

Bone metastases are at the center of advanced prostate cancer care, with over 90% of patients with metastatic prostate cancer expected to have bone involvement. 1 These metastatic ...

In a live event, Vinay Minocha, MD, discusses the addition of darolutamide to androgen deprivation therapy for in patients ...

TALKING about their below-the-belt health isn’t exactly a chat most men are rushing to have. But the fact remains that ...

INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, ...

Advanced Imaging Uncovers Hidden Metastases in High-Risk Prostate Cancer Cases Jan. 3, 2025 — A new study has found that many cases of high-risk nonmetastatic hormone-sensitive prostate cancer ...

Evan Y. Yu, MD, discusses the therapeutic options for metastatic castration-resistant prostate cancer (mCRPC) included in the National Comprehensive Cancer Network (NCCN) guidelines, such as ...

Prostate cancer is rapidly emerging as a significant health challenge in China, with the incidence rate steadily rising.